Glecaprevir/Pibrentasvir (Maviret®)

Assessment Status Assessment process complete
HTA ID -
Drug Glecaprevir/Pibrentasvir
Brand Maviret®
Indication For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6.
Assessment Process
Rapid review commissioned 11/07/2017
Rapid review completed 17/08/2017
Rapid review outcome Full pharmacoeconomic assessment not recommended.